SS-31 — known in the drug world as elamipretide — is one of the more serious peptides on this list, because a real biotech company has been testing it in proper clinical trials. But 'in trials' is not the same as 'approved.' Here's the honest picture: a genuinely interesting mitochondria-targeting molecule, real clinical research underway, mixed results so far, and no approval yet.

What SS-31 actually is

SS-31 is a small peptide — a short chain of amino acids (the building blocks of protein). What makes it unusual is its target: the mitochondria, the tiny structures inside your cells that act like power plants, turning food into usable energy. SS-31 is designed to reach and support a part of the mitochondria's inner membrane. In the pharmaceutical world it has the proper drug name elamipretide (and an older code, MTP-131).

What it's studied for

In clinical trials, SS-31 / elamipretide has been studied for:

  • Mitochondrial diseases — rare conditions where the cell's energy factories don't work properly
  • Heart conditions, where the heart muscle's energy is affected
  • Certain eye conditions linked to ageing of the retina
  • Cellular energy and age-related decline more broadly

That's a serious research programme — but a research programme is exactly what it still is.

What the evidence really shows

Because SS-31 has been through actual clinical trials, we know more about it than about many grey-market peptides. But the results so far have been mixed — some trials have been disappointing or didn't meet their main goals, and the work is ongoing. That's normal in drug development: many promising candidates take years, and some never make it to approval. The key point is that no major regulator has approved it, so its benefit and safety picture in real-world use isn't settled.

What the research points to

  • A well-defined scientific target (the mitochondria, the cell's energy factories)
  • Real clinical trials run by a biotech company — more rigour than most peptides
  • Early interest for mitochondrial, heart, and eye conditions

What it does NOT prove

  • That it's a proven, approved treatment for any condition
  • That grey-market 'SS-31' is safe or even the real thing
  • That it safely 'boosts energy' or slows ageing in healthy people

Who talks about it — and why to be careful

SS-31 shows up in longevity and biohacking circles, often framed as a 'mitochondrial upgrade.' Remember two things: the version being carefully tested in trials is not the same as a vial bought online, and 'in trials' means the science isn't finished. If you or a family member has a mitochondrial or heart condition, clinical trials and specialist doctors are the right route — not the grey market.

What this does not mean

  • This does not mean SS-31 is an approved medicine — it's still investigational and in clinical trials.
  • This does not mean grey-market 'SS-31' is safe or genuine; unregulated products aren't checked for purity or safety.
  • This is general education, not medical advice or a recommendation to use SS-31.